^
    Back
    Association details:
    Biomarker:CXCL8 elevation
    Cancer:Gastric Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    104P - Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)

    Published date:
    09/14/2020
    Excerpt:
    The elevation of IL-6 level at 4 weeks were detected in 8 (35%) of 23 responders and in only 2 (15%) of 13 non-responders (P = 0.21)….This study identified baseline plasma levels of IL-8 and sVCAM-1 as potential prognostic markers corresponding to favorable OS for combination therapy of PTX, RAM plus Nivo in patients with AGC. In addition, the increase in IL-6 level at 4 weeks may predict clinical benefit from the combination therapy.
    Secondary therapy:
    paclitaxel